| Transaction Value | ₹6.75 CrWarrant Conversion |
|---|---|
| Market Cap | ₹122.25 CrSmall Cap |
| Revenue TTM | ₹132.31 CrOperating |
| PE TTM | 47.82Valuation |
| Deal value | ₹13.95 Cr |
| Share of market cap | 11.4% |
| Share of annual revenue | 10.5% |
Key highlights
- Acquisition of 3,37,500 equity shares via conversion of warrants
- Total transaction value across promoter group entities totals ₹6.75 crore
- Srinidhi Fine Chemicals LLP acquired the largest block of 2,10,000 shares
- Post-allotment stake for Srinidhi Fine Chemicals LLP stands at 35.13 percent
- Other participating promoters include Narhari Belide and Vupparapalli Chandrasekhar
Warrant Conversion Details
Four entities from the promoter and promoter group exercised their right to convert warrants into equity shares of Novelix Pharmaceuticals. Srinidhi Fine Chemicals LLP led the transaction by acquiring shares worth 4.2 crore, while Narhari Belide, Vupparapalli Chandrasekhar, and Neha Gattu contributed the remaining amount. These allotments were executed on a preferential basis, following the earlier issuance of warrants.
The acquisition represents a significant commitment from the leadership group, consolidating their voting rights and equity interest in the pharmaceutical distribution and retail entity.
Business and Financial Context
Novelix Pharmaceuticals Limited, formerly known as Trimurthi Limited, operates primarily in the specialty retail and pharmaceutical sectors. The company reported an annual operating revenue of 132.31 crore for the previous fiscal year, marking a growth of over 330 percent year-on-year. While net profits reached 2.56 crore annually, the latest quarterly figures show a profit of 0.91 crore.
The stock maintains a momentum score of 61.75 and has traded between a 52-week low of 38 and a high of 92.
Corporate Transformation
- The company recently rebranded from Trimurthi Limited to Novelix Pharmaceuticals Limited to align with its core business focus
- Headquartered in Hyderabad, the firm maintains a presence in the competitive pharmaceutical retail landscape of Telangana
- Current promoter holding stands at 50.57 percent prior to the full impact of these recent warrant conversions
- The firm carries a Piotroski Score of 5, indicating average financial strength and operational efficiency
- Sector performance for retailing has seen a 100.99 percent growth in net profit year-on-year
Industry Landscape
The Indian specialty retail and pharmaceutical distribution market is experiencing a transition toward more organized structures. Mid-cap companies like Novelix are navigating a landscape shaped by increased regulatory oversight and the need for efficient supply chain management. The sector has seen robust revenue growth recently, with industry-wide net profit improvements.
Strategic stake increases by promoters often occur during periods of corporate restructuring or when leadership seeks to demonstrate long-term alignment with the company's growth trajectory and operational scaling.
| Share price | ₹69.4 |
|---|---|
| Market capitalisation | ₹122.25 Cr |
| Revenue (annual) | ₹132.31 Cr |
| Net profit (annual) | ₹2.56 Cr |
| Revenue (latest quarter) | ₹25.19 Cr-47.95% vs previous quarter |
| Net profit (latest quarter) | ₹0.91 Cr-9.21% vs previous quarter |
| P/E (TTM) | 47.82×Sector 76× |
| Promoter holding | 50.57%-1.41% QoQ |
| FII holding | 0%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Novelix Pharmaceuticals Limited announcing disclosure of share acquisition under Regulation 7(2) of SEBI PIT Regulations. Market figures from a third-party data provider.
